Document is current
Any future updates will be listed below
-
Authors
Zhang, Qi https://orcid.org/0000-0002-2639-9158
Tang, Weichun
Stancanelli, Eduardo
Jung, Eunkyung
Syed, Zulfeqhar https://orcid.org/0000-0002-5825-9782
Pagadala, Vijayakanth
Saidi, Layla
Chen, Catherine Z. https://orcid.org/0000-0002-6900-6553
Gao, Peng
Xu, Miao
Pavlinov, Ivan
Li, Bing
Huang, Wenwei https://orcid.org/0000-0002-7727-9287
Chen, Liqiang
Liu, Jian
Xie, Hang https://orcid.org/0000-0001-8318-5554
Zheng, Wei https://orcid.org/0000-0003-1034-0757
Ye, Yihong https://orcid.org/0000-0002-9512-7922
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (DK075143)
- License Information
-
More Information
Article History
Received: 14 March 2023
Accepted: 31 August 2023
First Online: 18 September 2023
Competing interests
: J.L. is a founder and the chief scientific officer for Glycan Therapeutics. V.P. is a chief operating officer for Glycan Therapeutics. Both J.L. and V.P. have equities for the company. Other authors declare no competing interests.
